MedTrace Logo

Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer

NCT00741221 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-10-04

No results posted yet for this study

Summary

This trial will evaluate the efficacy and safety of pemetrexed and bevacizumab combination in patients with pretreated, advanced non small cell lung cancer (NSCLC).

Conditions

  • Non-small-cell Lung Cancer

Interventions

DRUG

Pemetrexed

Pemetrexed (IV) 500 mg/m2 on day 1 every 3 weeks for 6 cycles

DRUG

Bevacizumab

Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles After the end of the 6 cycles Bevacizumab will be administered alone at the dose of 15 mgr/Kgr (IV) every 3 weeks until disease progression

Sponsors & Collaborators

  • Hellenic Oncology Research Group

    lead OTHER

Principal Investigators

  • Sofia Agelaki, MD · University Hospital of Crete, Dep of Medical Oncology

  • Manolis Kontopodis, MD · University Hospital of Crete

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00741221 on ClinicalTrials.gov